Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

NCT ID: NCT01499732

Last Updated: 2013-05-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 15 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-12-31
• Study Completion Date: 2012-11-30

Brief Summary

Premature Endothelial Dysfunction is present in patients with early rheumatoid arthritis.

Conditions

Premature Endothelial Dysfunction; Rheumatoid Arthritis; Healthy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Early Rheumatoid Arthritis

Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms \< or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)

No interventions assigned to this group

Healthy subjects without rheumatoid arthritis

Healthy subjects without rheumatoid arthritis

No interventions assigned to this group

Established Rheumatoid Arthritis

Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms \> or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (\> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

Group 1

1. Subjects currently experiencing active early RA (duration of symptoms ≤ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.

2. Subjects with early RA must be drug naïve (no prior treatment with traditional disease-modifying antirheumatic drugs (DMARDs), or biologic response modifying agents).

Group 2

3. Subjects currently experiencing active established RA (duration of symptoms ≥ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.

4. Subjects with active established RA currently receiving methotrexate (MTX), must have received it for at least 12 weeks, and at a stable dose (≥15mg/week) for at least 6 weeks prior to screening. They must be biologic drug naïve. These subjects must receive at least 5 mg oral folic acid weekly.

5. Subjects diagnosed with RA must be seropositive with documented rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti CCP) positivity. If a documented history of RF or anti CCP positivity is not available, RF and anti CCP titers will be obtained at screening Group 3

6. Healthy subjects without RA.

7. All subjects must have sitting diastolic BP ≤90 mm Hg and/or sitting systolic BP ≤ 140 at screening

8. Subjects must have fasting plasma glucose (FPG) of ≤ 100 mg/dL.

9. If subjects with established RA are receiving an oral corticosteroid, the dose must be ≤7 mg/day prednisone (or equivalent) and stable for at least 28 days prior to screening.

10. Subjects able and willing to give written informed consent and comply with the requirements of the study protocol. Informed consent must be obtained prior to any study-related procedures.

A copy of the signed informed consent form must be given to the subject

11. Patients must have a BMI of less than 42

Exclusion Criteria

1. Major surgery (including joint surgery) within 8 weeks prior to screening.

2. Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome). Prior history of or current inflammatory joint disease other than RA (gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis and psoriatic arthritis)

3. Functional class IV as defined by ACR Classification of Functional Status in RA

4. Current treatment with any traditional DMARDs other than MTX within 4 weeks before the screening visit (For subjects with established RA). Current or prior use of Leflunomide will be exclusionary.

5. Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before screening

6. Exposure to any Biologic Response Modifying Agent for RA

7. Intraarticular or parenteral corticosteroids within 6 weeks prior to screening (For subjects with established RA)

8. Exclusionary laboratory: Serum creatinine >2 mg/dL, ALT or AST > 2.0 x ULN, total bilirubin > 2.0 x ULN, platelet count <100 x 10⁹ /L, hemoglobin < 8.5 g/dL, WBC count < 1,000/mm³ , absolute neutrophil count < 1,000/ mm³, absolute lymphocyte count < 500/mm³, triglycerides >400 mg/dL, Serum potassium <3.5 or >5.5 mEq /L without medication, serum albumin <2.5 g/dL, Gamma GT 3.0 x UNL

9. Smokers (use of tobacco products in the recent past < 6 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports cigarette use or has a urine cotinine greater than 200 ng/mL.

10. Pregnant women or nursing mothers

11. Females of child bearing potential who are not using reliable means of contraception

12. Evidence of serious uncontrolled concomitant cardiovascular (including known CAD, HTN, or hyperlipidemia), nervous system, pulmonary, renal, hepatic, endocrine or GI disease.

13. Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel syndrome, where flares are commonly treated with corticosteroids.

14. History or presence of severe bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).

15. History of cardiovascular abnormalities including myocardial infarction, angina pectoris, hypertensive encephalopathy, stroke, transient ischemic attack, valvular heart disease, ventricular arrhythmia A-V block, atrial fibrillation or cardiac revascularization/angioplasty. Symptoms or clinical evidence of congestive heart failure or known left ventricular ejection fraction < 40%.

16. Medical history of clinically significant ECG abnormalities, including history of a prolonged QT-interval syndrome.

17. History of autonomic dysfunction

18. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections such as atypical mycobacterial disease, hepatitis B and C, HIV, herpes zoster, or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.

19. Any malignancy except for skin cancer (basal cell or squamous cell) diagnosed within the previous 5 years

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Orrin M Troum, M.D. and Medical Associates

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Orrin M Troum, MD

Role: PRINCIPAL_INVESTIGATOR

Orrin M. Troum, MD and Medical Associates

Locations

Orrin M. Troum, MD and Medical Associates

Santa Monica, California, United States

Countries

United States

Other Identifiers

IM101-320

Identifier Type: -

Identifier Source: org_study_id